Synthesis, biological evaluation, and studies of lantadene-derived pentacyclic triterpenoids as anticancer agents targeting IKK-β.

We report the anticancer activity, structure-activity relationships (SAR), molecular mechanism, and docking studies of nine pentacyclic triterpenoids derived from lantadene A. The NCI-60 cytotoxicity screening of synthesized compounds on 60 human tumor cell lines, representing nine different cancers revealed that compound , bearing dual C-3 and C-22 butyryloxy substitutions at the pentacyclic triterpenoid scaffold, displays remarkable potency with mean growth inhibition of 98.7% at 10 μM.

Optimization and purification of a novel calcium-independent thermostable, α-amylase produced by Bacillus licheniformis UDS-5.

Microbial amylases should essentially remain active at higher temperatures, and in the alkaline pH and a range of surfactants to be suitable as detergent additives. In the present study, a thermophilic amylase producing bacterium, Bacillus licheniformis UDS-5 was isolated from Unai hot water spring in Gujarat, India. It was identified as a potent amylase producer during starch plate-based screening process.

Isolation and characterization of a blue coloured three coordinate Cu(I)-radical complex with an S donor set.

A stable three coordinate Cu(I)-radical complex with an S donor set having the general formula of [Cu(S-NHCH)(SS-NHCS)] (1) was isolated as dark blue needles. Interestingly, this complex possesses a zwitterionic ligand, S-NHCH, which is coordinated to the central Cu(I) ion its S-atom [S-NHCH C4-thiolate functionalized C2-protonated zwitterionic N-hetero cyclic carbene; SS-NHCS˙ NHC-based dithiolene radical anion]. 1 has been structurally characterized by single-crystal X-ray diffraction, and further characterized by UV-vis, IR, XPS, and EPR spectroscopy.

A Comparative Analysis of Generic Drug Assessment and Regulatory Approval in the USA, Europe and India.

The Abbreviated New Drug Application (ANDA) is used for the regulatory submission of generic drugs, which are pharmaceutical equivalents to brand-name drugs and distributed without patent protection. Different countries have their own regulatory requirements for the approval of generic drugs, enforced by authorities such as the CDSCO in India, EDQM in Europe, and USFDA in the United States. This review aims to compare the regulatory processes and requirements for generic drug approval in India, Europe, and the US, highlighting key differences and challenges.